HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Rui-Sheng Duan Selected Research

Experimental Autoimmune Neuritis

1/2019Sulfatides ameliorate experimental autoimmune neuritis by suppressing Th1/Th17 cells.
1/2017Parthenolide inhibits the initiation of experimental autoimmune neuritis.
4/2016Activation of the adenosine A2A receptor exacerbates experimental autoimmune neuritis in Lewis rats in association with enhanced humoral immunity.
4/2014Therapeutic potential of atorvastatin-modified dendritic cells in experimental autoimmune neuritis by decreased Th1/Th17 cytokines and up-regulated T regulatory cells and NKR-P1(+) cells.
1/2011Atorvastatin ameliorates experimental autoimmune neuritis by decreased Th1/Th17 cytokines and up-regulated T regulatory cells.
2/2009Administration of dehydroepiandrosterone ameliorates experimental autoimmune neuritis in Lewis rats.
5/2007Apolipoprotein E deficiency enhances the antigen-presenting capacity of Schwann cells.
5/2007Aggravation of experimental autoimmune neuritis in TNF-alpha receptor 1 deficient mice.
2/2007IL-18 deficiency inhibits both Th1 and Th2 cytokine production but not the clinical symptoms in experimental autoimmune neuritis.
8/2004CCR5 deficiency does not prevent P0 peptide 180-199 immunized mice from experimental autoimmune neuritis.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Rui-Sheng Duan Research Topics

Disease

20Experimental Autoimmune Myasthenia Gravis (Autoimmune Experimental Myasthenia Gravis)
07/2021 - 12/2002
11Autoimmune Diseases (Autoimmune Disease)
07/2021 - 05/2003
11Experimental Autoimmune Neuritis
01/2019 - 02/2004
10Myasthenia Gravis
06/2022 - 06/2015
3Guillain-Barre Syndrome
01/2019 - 05/2007
3Neurodegenerative Diseases (Neurodegenerative Disease)
06/2008 - 11/2004
3Gliosis
05/2007 - 11/2004
2Brain Injuries (Brain Injury)
06/2014 - 11/2004
2Alzheimer Disease (Alzheimer's Disease)
08/2011 - 06/2008
2Status Epilepticus (Complex Partial Status Epilepticus)
08/2009 - 02/2007
2Body Weight (Weight, Body)
07/2004 - 03/2003
1Atherosclerosis
02/2018
1Infections
04/2016
1Wounds and Injuries (Trauma)
04/2016
1Spasm (Spasms)
06/2014
1Cerebral Palsy (Spastic Diplegia)
06/2014
1Cognitive Dysfunction
08/2011
1Epilepsy (Aura)
08/2011
1Memory Disorders (Memory Loss)
08/2009
1Polyneuropathies (Polyneuropathy)
05/2007
1Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental)
01/2005
1Disease Progression
08/2004
1Demyelinating Diseases (Demyelinating Disease)
02/2004
1Muscle Weakness
12/2002

Drug/Important Bio-Agent (IBA)

7CytokinesIBA
01/2016 - 02/2007
5AntibodiesIBA
01/2021 - 12/2002
5Cholinergic ReceptorsIBA
01/2021 - 03/2003
5Atorvastatin (Lipitor)FDA Link
06/2019 - 01/2011
3Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
11/2019 - 09/2015
3Interleukin-17 (Interleukin 17)IBA
08/2017 - 04/2014
3Freund's AdjuvantIBA
06/2015 - 12/2002
3Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
06/2014 - 12/2002
3AntigensIBA
05/2007 - 02/2004
3Peptides (Polypeptides)IBA
05/2007 - 08/2004
3Interleukin-10 (Interleukin 10)IBA
06/2006 - 02/2004
2Therapeutic UsesIBA
06/2022 - 06/2006
2Ursolic AcidIBA
05/2019 - 04/2015
2Aspartic Acid (Aspartate)FDA Link
08/2017 - 06/2015
2interleukin-1beta-converting enzyme inhibitorIBA
08/2017 - 06/2015
2Pharmaceutical PreparationsIBA
01/2016 - 06/2015
2Interleukin-6 (Interleukin 6)IBA
06/2014 - 05/2007
2Dehydroepiandrosterone (DHEA)IBA
02/2009 - 03/2003
2Interleukin-18 (Interleukin 18)IBA
05/2007 - 02/2007
2Apolipoproteins E (ApoE)IBA
05/2007 - 02/2004
2ApolipoproteinsIBA
05/2007 - 02/2004
2NeurotoxinsIBA
02/2005 - 11/2004
2Kainic Acid (Kainate)IBA
02/2005 - 11/2004
1glucose-mannose-glucoseIBA
06/2022
1Fingolimod Hydrochloride (FTY720)FDA Link
07/2021
1Calcitriol Receptors (Calcitriol Receptor)IBA
01/2021
1Sulfoglycosphingolipids (Sulfatides)IBA
01/2019
1Toll-Like Receptor 9IBA
01/2018
1OligodeoxyribonucleotidesIBA
01/2018
1Interleukin-1 (Interleukin 1)IBA
08/2017
1parthenolideIBA
01/2017
1GangliosidesIBA
04/2016
1Adenosine A2A Receptor (Adenosine A2A Receptors)IBA
04/2016
12- (4- (2- carboxyethyl)phenethylamino)- 5'- N- ethylcarboxamidoadenosineIBA
04/2016
1astilbinIBA
01/2016
1CurcuminIBA
01/2016
1fasudil (AT 877)IBA
01/2016
1C-Reactive ProteinIBA
06/2014
1Nitric Oxide Synthase (NO Synthase)IBA
06/2014
1Memantine (Namenda)FDA Link
08/2011
1Saline SolutionIBA
08/2009
1Valproic Acid (Depakote)FDA LinkGeneric
08/2009
1ChemokinesIBA
06/2008
1Type I Tumor Necrosis Factor ReceptorsIBA
05/2007
1Myelin P0 Protein (Myelin Protein Zero)IBA
02/2007
1N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA
02/2007
1Chemokine CCL19IBA
06/2006
1Glial Fibrillary Acidic ProteinIBA
02/2005
1Glutamic Acid (Glutamate)FDA Link
02/2005
1Transforming Growth Factor beta (TGF-beta)IBA
01/2005
1Interleukin-12 Subunit p35IBA
11/2004
1Interleukin-12 (IL 12)IBA
11/2004
1MitogensIBA
08/2004
1Immunoglobulin G (IgG)IBA
07/2004

Therapy/Procedure

3Immunotherapy
12/2020 - 05/2003
3Therapeutics
08/2017 - 03/2003
1Activities of Daily Living (ADL)
06/2022
1Aftercare (After-Treatment)
11/2019
1Acupuncture Therapy
06/2014
1Intranasal Administration
02/2005